PTEN is a suppressor of the PI3K-AKT pathway, and genetic alterations/deletions in PTEN are commonly seen in prostate cancer, with some estimates suggesting decreased PTEN expression in over 80% of primary prostate cancers [166]. This evidence concerns the gene PTEN and prostate cancer.